Table 1.
The interaction of microRNA (miRNA) with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) subdivided by gene family, miRNA construct identified, cell model and tissue type, and an analysis of the degrees of validation
| miRNA gene family | miRNA examined | Cell model | Tissue type | Biological evidence | Luciferase reporter assay | MRE mutated | References |
|---|---|---|---|---|---|---|---|
| miR-9 | miR-9 | TU212, Hep-2 | Laryngocarcinoma | Yes | Yes | Yes | Lu et al. 2016 |
| miR-17 | miR-17 | DU145 | Prostate cancer | Yes | Yes | Yes | Poliseno et al. 2010a |
| miR-17-5p | NIH3T3 | Mouse fibroblast | Yes | Yes | Yes | Xiao et al. 2008 | |
| miR-18a-5p | U2OS | Osteosarcoma | Yes | NA | NA | Fei et al. 2018 | |
| miR-20a | DU145/HEK 293T/HUVEC/HEK 293 | Prostate cancer/SV40 large T antigen model/endothelial/model line | Yes/yes/yes/yes | NA/yes/yes/yes | NA/yes/yes/yes | Poliseno et al. 2010b; Zhang et al. 2015; Wang et al. 2017a; Jiang et al. 2018 | |
| miR-93 | MCF-7, MDA-MB-231 | Breast cancer | Yes | Yes | Yes | Li et al. 2017a | |
| miR-106a | SGC7901/PC-3 | Gastric cancer/prostate cancer | Yes/yes | Yes/yes | Yes/NA | Fang et al. 2013/Lu et al. 2019 | |
| miR-106a-3p | HT29 | Colorectal adenocarcinoma | Yes | Yes | Yes | Qin et al. 2018 | |
| miR-106b | MCF-7 and MDA-MB-231 | Breast cancer | Yes | Yes | Yes | Li et al. 2017a | |
| miR-19 | miR-19 | DU145 | Prostate cancer | Yes | Yes | Yes | Poliseno et al. 2010a |
| miR-19a | NCTC1469 cells and HEP1–6/HOS | Macrophage-like and hepatocellular carcinoma/osteosarcoma | Yes/yes | Yes/yes | NA/yes | Dou et al. 2015; Zhao et al. 2017 | |
| miR-19a-3p | U2OS | Osteosarcoma | Yes | Yes | Yes | Zhang et al. 2019 | |
| miR-19b | DU145/H9C2/MDA-MB-231 | Prostate cancer/rat cardiomyocyte/breast cancer | Yes/yes/yes | NA/NA/yes | NA/NA/yes | Poliseno et al. 2010b; Xu et al. 2016; Li et al. 2017b | |
| miR-21 | miR-21 | SK-HEP-1 and SNU-182/VSMC/A549 | Hepatocellular carcinoma/vascular smooth muscles/non-small lung cancer | Yes/yes/yes | Yes/NA/NA | NA/NA/NA | Meng et al. 2006, 2007; Ji et al. 2007; |
| miR-22 | miR-22 | DU145 | Prostate cancer | Yes | Yes | Yes | Poliseno et al. 2010a |
| miR-23 | miR-23a-3p | HEK 293 | Model | Yes | Yes | NA | Lozano-Bartolomé et al. 2018 |
| miR-23b-3p | A-498 | Kidney carcinoma | Yes | Yes | NA | Zaman et al. 2012 | |
| miR-25 | miR-25 | DU145 | Prostate cancer | Yes | Yes | Yes | Poliseno et al. 2010a |
| miR-92a | U2OS/U14/A549 | Osteosarcoma/cervical cancer/adenocarcinoma | Yes/yes/yes | Yes/yes/yes | Yes/yes/yes | Ren et al. 2016; Li et al. 2017b; Xiao et al. 2017 | |
| miR-26 | miR-26a | HEK 293 | Model | Yes | Yes | Yes | Huse et al. 2009 |
| miR-33 | miR-33a | HEK 293 | Model | Yes | Yes | NA | Ling et al. 2013 |
| miR-103 | miR-103 | UMUC2 and 5637 | Bladder cancer | Yes | Yes | Yes | Yu et al. 2019 |
| miR-103a | HEK 293/HEK 293 | Model/model | Yes/yes | Yes/yes | Yes/yes | Geng et al. 2014; Hsu et al. 2017 | |
| miR-107 | EJ cells | Bladder cancer | Yes | Yes | Yes | Chi et al. 2018; Yu et al. 2019 | |
| miR-130 | miR-130b | HEK 293T /HCCLM3 and HepG2 | SV40 large T antigen model/hepatocellular carcinoma | Yes/yes | Yes/yes | Yes/yes | Chang et al. 2016; Miao et al. 2017 |
| miR-136 | miR-136 | U343 | Glioblastoma | Yes | Yes | Yes | Lee et al. 2010 |
| miR-144 | miR-144 | U343 | Glioblastoma | Yes | Yes | Yes | Lee et al. 2010 |
| miR-154 | miR-494 | Huh-7/INS-1 | Hepatocellular carcinoma/rat insulinoma | Yes/yes | NA/yes | NA/yes | He et al. 2017; Pollutri et al. 2018 |
| miR-494-3p | SMMC-7721 and HCCLM3 | HPV-related endocervical adenocarcinoma | Yes | Yes | Yes | Lin et al. 2018 | |
| miR-181 | miR-181-5p | HEK 293 | Model | Yes | Yes | NA | Lozano-Bartolomé et al. 2018 |
| miR-193 | miR-193a | 786-O cells | Renal cell carcinoma | Yes | Yes | Yes | Liu et al. 2017 |
| miR-214 | miR-214 | A2780CP and HIOSE-80 | Ovarian cancer | Yes | Yes | Yes | Yang et al. 2008 |
| miR-216 | miR-216a | Mouse glomerular mesangial cells | Normal kidney | Yes | Yes | Yes | Kato et al. 2009 |
| miR-216a+miR-217 | PLC/-PRF/5 | Hepatocellular carcinoma | Yes | Yes | Yes | Xia et al. 2013 | |
| miR-217 | miR-217 | mouse glomerular mesangial cells/HEK 293T | Normal kidney/SV40 large T antigen model | Yes/yes | Yes/yes | Yes/yes | Kato et al. 2009; Nie et al. 2018 |
| miR-221 | miR-222 | OVCAR-3 | Ovarian cancer | Yes | Yes | Yes | Zhou et al. 2012; Gong et al. 2018 |
| miR-302 | miR-302 | DU145 | Prostate cancer | Yes | Yes | Yes | Poliseno et al. 2010a |
| miR-506 | miR-510-3p | NCI-H441 and PC-9 | Non-small lung cancer | Yes | Yes | Yes | Yu et al. 2019 |
Validation ranges from having any biological evidence such as western blots and qPCR data, to analyses of the isolated fragment of the 3′UTR in a luciferase reporter assay, which may have the miRNA recognition element (MRE) mutated to further demonstrate loss of repression.
(NA) not applicable.